MRNA has ripped 27% in a single week to $182.56, and the shorts who built the largest position of the past year are now covering at speed.
The scale of the short retreat is the week's defining feature. Short interest has fallen 30% over the past month — from roughly 50 million shares to 35.4 million — with the most dramatic leg lower happening in early September, when positions dropped by nearly 14 million shares in just a few sessions. At 9.1% of the free float, shorts are still a meaningful presence, but the direction is unambiguous. Borrow conditions tell the same story: availability has opened sharply, climbing to 628% — meaning roughly six shares remain available to borrow for every one already lent out — the loosest the lending market has been all year. Cost to borrow, at 0.59%, is essentially at a generic rate. There is no squeeze pressure here; shorts who want out face no friction doing so. Options positioning has also rotated. The put/call ratio has dropped to 1.05, well below its 20-day average of 1.18 and approaching a one-standard-deviation discount to recent norms. Through most of August, the PCR was running near its 52-week high of 1.51. That defensive overhang is unwinding quickly alongside the price move.
The Street is watching MRNA's re-rating with a mix of disbelief and delayed upgrades. Consensus sits at hold, and the analyst community's collective mean price target of around $120 now sits roughly 35% below the current price — a significant dislocation that reflects how far the stock has outrun formal covering. The most recent analyst moves show a clear pattern: nearly every major firm raised targets over August but kept neutral or negative ratings. Goldman Sachs lifted from $67 to $120 while staying Neutral. JPMorgan raised from $40 to $77 while keeping Underweight. Morgan Stanley moved from $39 to $89 at Equal-Weight. Barclays went from $48 to $125 without changing its stance. Argus Research was the outlier, upgrading to Buy with a $180 target — essentially the only firm willing to validate the move in real time. Rothschild went the other way, downgrading to Sell in early September even as it doubled its own target to $81. The net message from the Street: targets have been thoroughly reset but conviction in the rally remains scarce. Forward EPS growth expectations, however, rank in the 89th percentile on a 12-month basis — the fundamental revision cycle is turning, even if trailing profitability scores remain depressed.
Institutional flows suggest the big money began moving earlier than most recognised. FMR (Fidelity) added over 6 million shares in the period to end-August, lifting its stake to 12.96% of shares. Capital Research built a new 5.6% position, disclosed in August. T. Rowe Price added nearly 4.9 million shares, bringing its holding to 1.4% of the company. These are not passive rebalancing moves — they represent active accumulation ahead of the rally's sharpest phase. CEO Stéphane Bancel still holds 5.56% of the company, a figure that has barely shifted. On the insider trading side, President Stephen Hoge and CFO James Mock both executed pre-arranged 10b5-1 sales in September — Hoge selling roughly $11.7 million across two days, Mock selling nearly $4.7 million. These are plan-driven, not discretionary, and carry limited signal about management's conviction on direction. No 13D activist has registered on the share register; all major 5%-plus holders are filing passive Schedule 13G.
The next earnings event is scheduled for November 5. Recent history at earnings is mixed but instructive: the August 6 print produced a 5.2% single-day gain that extended to 13% over the following week, while the July 31 release saw an immediate 4.8% drop followed by a partial 2.2% five-day recovery. Both moves are modest relative to the stock's recent weekly swings. The ORTEX short score has drifted down from 56.4 on September 9 to 49.4 today, confirming that the short thesis has broadly deflated alongside the covering. BNTX, MRNA's closest peer at 75% correlation, gained just 4.3% on the week — a fraction of MRNA's 27% — while ARCT fell 9.2%, underlining how idiosyncratic this move has been.
The November 5 earnings date becomes the next focal point: the question is whether the Street's lagging price targets catch up to the stock before the print, or whether the remaining 9% short interest provides the next leg of the covering story.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
